

CYTRX CORP
Form 10-Q
August 09, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

For the quarterly period ended June 30, 2010

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

For the transition period from to

Commission file number 0-15327

CytRx Corporation
(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or
organization)

58-1642740
(I.R.S. Employer Identification No.)

11726 San Vicente Blvd., Suite 650
Los Angeles, CA
(Address of principal executive offices)

90049
(Zip Code)

(310) 826-5648
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Edgar Filing: CYTRX CORP - Form 10-Q

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input checked="" type="checkbox"/>	Non-accelerated filer <input type="checkbox"/>	Smaller reporting company <input type="checkbox"/>
(Do not check if a smaller reporting company)			

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes No

Number of shares of CytRx Corporation common stock, \$.001 par value, outstanding as of August 6, 2010: 109,128,638 million shares exclusive of treasury shares.

CYTRX CORPORATION

FORM 10-Q

TABLE OF CONTENTS

	Page
PART I. — FINANCIAL INFORMATION	
Item 1. Financial Statements	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 3. Quantitative and Qualitative Disclosures About Market Risk	17
Item 4. Controls and Procedures	17
PART II. — OTHER INFORMATION	
Item 1A. Risk Factors	17
Item 5. Other Information	18
Item 6. Exhibits	18
SIGNATURES	19
INDEX TO EXHIBITS	20

PART I — FINANCIAL INFORMATION

Item 1. — Financial Statements

CYTRX CORPORATION
CONDENSED BALANCE SHEETS
(Unaudited)

	June 30, 2010	December 31, 2009
ASSETS		
Current assets:		
Cash and cash equivalents	\$12,452,514	\$9,893,590
Marketable Securities	21,023,740	22,750,000
Investment in RXi Pharmaceuticals – at market	8,044,091	—
Receivable	59,314	139,680
Income taxes recoverable	519,158	519,158
Interest receivable	126,897	130,779
Assets held for sale	33,503	73,634
Prepaid expense and other current assets	679,589	1,088,074
Total current assets	42,938,806	34,594,915
Equipment and furnishings, net	375,228	174,959
Goodwill	183,780	183,780
Other assets	318,782	323,235
Total assets	\$43,816,596	\$35,276,889
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$588,802	\$1,066,055
Accrued expenses and other current liabilities	3,076,451	2,492,450
Warrant liability	1,959,124	3,370,701
Total current liabilities	5,624,377	6,929,206
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding	—	—
Common stock, \$.001 par value, 175,000,000 shares authorized; 109,762,454 and 109,538,821 shares issued and outstanding at June 30, 2010 and December 31, 2009, respectively.	109,762	109,539
Additional paid-in capital	228,558,452	227,441,591
Accumulated comprehensive income, net of tax	8,044,091	—
Treasury stock, at cost (633,816 shares held at June 30, 2010 and December 31, 2009)	(2,279,238)	(2,279,238)
Accumulated deficit	(196,240,848)	(196,924,209)
Total stockholders' equity	38,192,219	28,347,683

Total liabilities and stockholders' equity	\$43,816,596	\$35,276,889
--	--------------	--------------

The accompanying notes are an integral part of these condensed financial statements.

CYTRX CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Revenue:				
Service revenue	\$—	\$963,667	\$—	\$2,446,495
Expenses:				
Research and development	3,073,059	1,363,794	5,118,868	4,412,546
General and administrative	2,060,266	1,928,355	4,705,376	4,411,126
	5,133,325	3,292,149	9,824,244	8,823,672
Loss before other income	(5,133,325)	(2,328,482)	(9,824,244)	(6,377,177)
Other income:				
Interest income	79,687	71,676	172,718	139,963
Other income, net	28,530	31,279	35,696	38,360
Gain on warrant derivative liability	1,278,884	—	1,411,577	—
Gain on sale of affiliate's shares – RXi Pharmaceutical	5,040,114	—	8,887,614	—
Net income (loss) before provision for income taxes	1,293,890	(2,225,527)	683,361	(6,198,854)
Provision for income taxes	—	—	—	—
Net income (loss)	\$1,293,890	\$(2,225,527)	\$683,361	\$(6,198,854)
Other comprehensive income (net of tax)				
Unrealized gain on available-for-sale securities	8,044,091	—	8,044,091	—
Comprehensive income	\$9,337,981	\$(2,225,527)	\$8,727,452	\$(6,198,854)
Basic net income (loss) per share	\$0.01	\$(0.02)	\$0.01	\$(0.07)
Basic weighted average shares outstanding	109,121,022	93,348,189	109,016,952	93,347,962
Diluted net income (loss) per share	\$0.01	\$(0.02)	\$0.01	\$(0.07)
Diluted weighted average shares outstanding	111,587,896	93,348,189	111,934,617	93,347,962

The accompanying notes are an integral part of these condensed financial statements

CYTRX CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

	Six Months Ended June 30,	
	2010	2009
Cash flows from operating activities:		
Net income (loss)	\$ 683,361	\$ (6,198,854)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	58,843	376,592
Retirement of fixed assets	30,171	—
Gain on sale of affiliate's shares	(8,887,614)	—
Fair value adjustment of warrant liability	(1,411,577)	—
Stock option and warrant expense	1,103,232	1,138,640
Net change in operating assets and liabilities	470,543	(2,273,377)
Net cash used in operating activities	(7,953,041)	(758,145)
Cash flows from investing activities:		
Purchase of marketable securities	(12,023,740)	(11,000,000)
Proceeds from matured marketable securities	13,750,000	—
Proceeds from sale of assets held for sale	40,131	—
Proceeds from sale of affiliate's shares	8,887,614	—
Purchases of equipment and furnishings	(289,283)	(145,373)
Net cash provided by (used in) investing activities	10,364,722	(11,145,373)
Cash flows from financing activities:		
Net proceeds from exercise of stock options	147,243	3,083
Net cash provided by financing activities	147,243	3,083
Net increase (decrease) in cash and cash equivalents	2,558,924	(18,099,289)
Cash and cash equivalents at beginning of period	9,893,590	25,041,772
Cash and cash equivalents at end of period	\$ 12,452,514	\$ 6,942,483

Supplemental disclosure of cash flow
information:

Cash received during the period as interest income	\$ 52,962	\$ 18,802
---	-----------	-----------

The accompanying notes are an integral part of these condensed financial statements.

CYTRX CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

June 30, 2010
(Unaudited)

1. Description of Company and Basis of Presentation

CytRx Corporation (“CytRx” or the “Company”) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology. CytRx’s drug development pipeline includes clinical development of three product candidates for cancer indications, including a recently-initiated Phase 2 proof-of-concept clinical trial with bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia, or B-CLL, two planned Phase 2 proof-of-concept clinical trial with bafetinib in patients with glioblastoma multiforme and advanced prostate cancer, three planned Phase 2 clinical trials for INNO-206 as a treatment for pancreatic cancer, gastric (stomach) cancer and soft tissue sarcomas, and a registration study of tamibarotene for the treatment of acute promyelocytic leukemia, or APL. In addition to its core oncology programs, CytRx is developing two drug candidates based on its molecular chaperone regulation technology, which are designed to repair or degrade mis-folded proteins associated with disease. Apart from its drug development programs, CytRx currently maintains a 17% equity interest in its former subsidiary, RXi Pharmaceuticals Corporation, or RXi. The Company’s current business strategy is to possibly spin-out its molecular chaperone regulation technology or seek one or more strategic partnerships to pursue the development of the technology.

The accompanying condensed financial statements at June 30, 2010 and for the three-month and six-month periods ended June 30, 2010 and 2009 are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Prior period figures have been reclassified, wherever necessary, to conform to current presentation. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2009 have been derived from the Company’s audited financial statements as of that date.

The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company’s audited financial statements in its Annual Report on Form 10-K for the year ended December 31, 2009. The Company’s operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

2. Recent Accounting Pronouncements

In January, 2010, the FASB issued ASU 2010-06, Improving Disclosures about Fair Value Measurements. The standard amends ASC Topic 820, Fair Value Measurements and Disclosures to require additional disclosures related to transfers in and out of Levels 1 and 2 and for activity in Level 3 and clarifies other existing disclosures requirements. The Company adopted ASU 2010-06 beginning January 1, 2010. This update had no impact on the Company’s financial statements.

3. Marketable Securities

The Company held \$21.0 million of marketable securities at June 30, 2010. The Company has classified these investments as available for sale. These investments are comprised of federally insured certificates of deposit in four accounts detailed as follows: \$5.0 million with a maturity date of July 29, 2010; \$7.5 million with a maturity date of September 30, 2010; \$5.0 million with a maturity date of January 27, 2011; and \$3.5 million with a maturity date of March 31, 2011.

4. Investment in RXi Pharmaceuticals

On June 30, 2010, the Company sold 2.0 million common shares for \$5.0 million, net of costs. Previously, the Company accounted for its investment in RXi using the equity method, under which the Company recorded its pro-rata share of the financial results of RXi against its investment in RXi. The investment balance in RXi was reduced to zero and the Company stopped recording its share of losses from RXi. As a consequence of this sale, the Company's ownership in RXi, approximately 3.1 million of common stock, was reduced to approximately 17%. The Company is now required to account for its investment under the cost method, and this investment is shown on the Balance Sheet at market value, based on RXi's closing stock price at June 30, 2010. The Company has classified the investment as available for sale, and the investment will be marked to market on a go-forward basis. At June 30, 2010, the investment had a market value of approximately \$8.0 million. The recording of this marked to market is reflected as other comprehensive income on the Consolidated Statements of Operations.

5. Assets Held for Sale

In May 2009, the Company substantially completed the initial phase of the closure of its drug discovery research at its laboratory facility in San Diego, California. The Company concluded that it will conduct its research and development activities through third parties for the foreseeable future. The Company has sublet the laboratory facility, sold some of the laboratory equipment and is actively searching for additional buyers. In the third quarter of 2009, the fixed assets related to the San Diego laboratory were re-allocated from Equipment and Furnishings to Assets Held for Sale and were written down to their estimated net realizable value as of September 30, 2009, which resulted in a charge of \$1.2 million for that quarter. In November 2009, the Company signed sublease agreements with two parties to sublet the facility for the remainder of the term of the lease, which expires in October, 2010. The Company recognized a lease accrual of \$254,000 as of September 2009; at June 30, 2010, the lease accrual was reduced to \$45,000.

As of June 30, 2010, the carrying amount of the assets held for sale approximated fair value. The costs associated with disposing of these assets held for sale are minimal.

6. Basic and Diluted Net Profit (Loss) Per Share

Basic net income (loss) per common share was computed using the weighted-average number of common shares outstanding. Diluted net income (loss) per common share was computed using the weighted-average number of common share and common share equivalents outstanding. Potentially dilutive stock options and warrants of 13.3 million shares and 11.3 million shares, respectively, for the three and six-month periods ended June 30, 2010 and 15.9 million shares and 15.8 million shares, respectively, for the three and six-month periods ended June 30, 2009, were excluded from the computation of diluted loss per share, where the effect would be anti-dilutive.

7. Warrant Liabilities

Liabilities measured at market value on a recurring basis include warrant liabilities resulting from our recent equity financing. In accordance with ASC 815-40 (formerly EITF (Emerging Issues Task Force) 00-19, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company's Own Stock, the warrant liabilities are being marked to market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method. The gain or loss resulting from the marked to market calculation is shown on the Statements of Operations as Gain on warrant derivative liability. The Company recognized a gain of \$1.3 million and \$1.4 million, respectively, for the three and six-month periods ending June 30, 2010.

8. Stock Based Compensation

CytRx Corporation

The Company has a 2000 Long-Term Incentive Plan under which an aggregate of 10.0 million shares of common stock were originally reserved for issuance. As of June 30, 2010, there were approximately 7.3 million shares subject to outstanding stock options and approximately 0.1 million shares available for future grant under this plan. This plan expired on August 6, 2010, when no additional shares will be available for grant under this plan.

The Company also has a 2008 Stock Incentive Plan under which 10.0 million shares of common stock were originally reserved for issuance. As of June 30, 2010, there were 1.1 million shares subject to outstanding stock options and 8.9 million shares available for future grant under this plan.

The Company has adopted the provisions of ASC 718 (previously SFAS No. 123(R), Share-Based Payment ("SFAS 123(R)")), which requires the measurement and recognition of compensation expense for all stock-based awards made

to employees and non-employees.

For stock options and stock warrants paid in consideration of services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC 718 (previously SFAS No. 123(R)), ASC 505-50 (previously Emerging Issues Task Force Issue No. 96-18 (“EITF 96-18”)), Accounting for Equity Instruments that are Issued to other than Employees for Acquiring, or in Conjunction with Selling Goods or Services and ASC 505 (previously EITF 00-18, Accounting Recognition for Certain Transactions involving Equity Instruments Granted to Other Than Employees), as amended.

7

Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.

At the 2009 Annual Meeting of Stockholders held on July 1, 2009, the Company's stockholders approved an amendment to the Company's 2000 Long-Term Incentive Plan to allow for a one-time stock option re-pricing program for employees and officers. Pursuant to the re-pricing program, 3,265,500 eligible stock options held by ten eligible employees and officers were amended to reduce the exercise prices of the options to \$1.15 per share, which was the closing sale price of the Company's common stock as reported on the Nasdaq Capital Market on the July 1, 2009 completion date of the re-pricing program, and to impose a new option vesting schedule. None of the amended options vested immediately. To the extent a participating employee's or officer's eligible options were vested on the amendment date, the amended options vested in full on December 31, 2009, so long as the employee or officer remained in the Company's employ through that date. To the extent a participating employee's or officer's eligible options were unvested as of July 1, 2009, the original scheduled vesting was suspended until December 31, 2009 and resumed after that date, so long as the employee or officer remained in the Company's employ through such date. The incremental cost of the re-pricing program was approximately \$0.4 million.

The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in the Company's unaudited interim statements of operations:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Research and development — employee	\$45,261	\$172,000	\$87,895	\$368,000
General and administrative — employee	338,456	297,000	483,404	572,000
Total employee stock-based compensation	\$383,717	\$469,000	\$571,299	\$940,000
Research and development — non-employee	\$24,990	\$10,000	\$53,312	\$19,000
General and administrative — non-employee	—	—	478,621	—
Total non-employee stock-based compensation	\$24,990	\$10,000	\$531,933	\$19,000

During the six-month period ended June 30, 2010, the Company issued stock options to purchase 645,000 shares of its common stock. The fair value of the stock options granted in the six-month period listed in the table below was estimated using the Black-Scholes option-pricing model, based on the following assumptions:

	Six Months Ended June 30,	
	2010	2009
Risk-free interest rate	2.37%-2.97%	1.90% - 2.37%
Expected volatility	92.5% - 99.4%	93.9% - 97.9%
Expected lives (years)	5 - 10	6
Expected dividend yield	0.00%	0.00%

The Company's computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For option grants issued during the six-month periods ended June 30, 2010 and 2009, the Company used a calculated volatility for each grant. The Company uses historical information to compute expected lives. In the six-month period ended June 30, 2010, the contractual term of the options granted was five to ten years and the Company used that term as the expected life. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. Based on historical experience, for the six-month periods ended June 30, 2010 and 2009, the Company has estimated an annualized forfeiture rate of 14% and 10%, respectively, for options granted to its employees, 2% and 1%, respectively, for options granted to senior management and 0% for each period for options granted to directors and non-employees. Compensation costs will be adjusted for future changes in estimated forfeitures. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. No amounts relating to employee stock-based compensation have been capitalized.

At June 30, 2010, there remained approximately \$2.4 million of unrecognized compensation expense related to unvested stock options granted to current and former employees, directors and consultants, to be recognized as expense over a weighted-average period of 1.07 years. Presented below is the Company's stock option activity:

	Six Months Ended June 30, 2010			Weighted Average Exercise Price
	Number of Options (Employees)	Number of Options (Non-Employees)	Total Number of Options	
Outstanding at January 1, 2010	8,012,090	995,000	9,007,090	\$ 1.02
Granted	250,000	395,000	645,000	\$ 1.05
Exercised	(223,633)	—	(223,633)	\$ 0.66
Forfeited or expired	(676,367)	(395,000)	(1,071,367)	\$ 1.07
Outstanding at June 30, 2010	7,362,090	995,000	8,357,090	\$ 1.07
Options exercisable at June 30, 2010	5,021,322	595,061	5,616,383	\$ 1.12

A summary of the activity for unvested stock options as of June 30, 2010, and changes during the quarter, is presented below:

	Number of Options (Employees)	Number of Options (Non-Employees)	Total Number of Options	Weighted Average Grant Date Fair Value per Share
Non-vested at January 1, 2010	3,013,690	449,920	3,463,610	\$ 0.81
Granted	—	—	—	\$—
Forfeited or expired	(51,525)	—	(51,525)	\$ 0.62
Vested	(621,397)	(49,981)	(671,378)	\$ 0.77
Non-vested at June 30, 2010	2,340,768	399,939	2,740,707	\$ 0.94

The following table summarizes significant ranges of outstanding stock options under the Company's plans at June 30, 2010:

Range of Exercise Prices	Number of Options	Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price	Number of Options Exercisable	Weighted Average Contractual Life	Weighted Average Exercise Price
0.30 - \$1.00	2,152,607	7.72	\$ 0.59	1,467,053	7.72	\$ 0.63
\$1.01 -1.50	5,676,483	6.74	\$ 1.12	3,621,330	6.74	\$ 1.15
1.51 - \$3.33	528,000	4.05	\$ 2.27	528,000	4.05	\$ 2.27
	8,357,090	6.83	\$ 1.06	5,616,383	6.83	\$ 1.12

The aggregate intrinsic value of outstanding options as of June 30, 2010 was \$10.3 million, which represents the difference between the fair market value of the underlying shares based on the closing price of the Company's common stock on June 30, 2010 of \$0.77 and the aggregate exercise price of the options.

9. Fair Value Measurements

Assets and liabilities recorded at fair value in balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows:

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at June 30, 2010 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I	Level II	Level III	Total
Cash and cash equivalents	\$ 12,453	\$ —	\$ —	12,453
Marketable securities	21,024	—	—	21,024
Investment in RXi Pharmaceutical market	8,044	—	—	8,044
Warrant liability	—	1,959	—	1,959

The following table summarizes fair value measurements by level at December 31, 2009 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I	Level II	Level III	Total
Cash and cash equivalents	\$ 9,894	\$ —	\$ —	9,894
Marketable securities	22,750	—	—	22,750

Liabilities measured at market value on a recurring basis include warrant liabilities resulting from recent equity financing. In accordance with ASC 815-40 (formerly EITF 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock), the warrant liabilities are being marked to market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with the Company's application of ASC 505-50. See Warrant Liabilities below.

The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.

The Company's non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. The Company's non-financial assets were not material at June 30, 2010 and June 30, 2009.

10. Liquidity and Capital Resources

At June 30, 2010, the Company had cash and cash equivalents of approximately \$12.5 million, marketable securities of approximately \$21.0 million, and held approximately 3.1 million shares of common stock of RXi Pharmaceuticals Corporation, or RXi, with a market value of approximately \$8.0 million based upon the closing price of the RXi common stock on that date. On March 26, 2010, the Company raised approximately \$3.8 million from the sale of 675,000 RXi shares, and on June 30, 2010, the company sold 2.0 million shares of the RXi common stock for \$5.0 million, net of costs. Management believes that the Company's current cash on hand, together with its marketable securities and proceeds from possible future sales of RXi shares, will be sufficient to fund its operations for the foreseeable future. The estimate is based, in part, upon the Company's currently projected expenditures for the remainder of 2010 and the first six months of 2011 of approximately \$17.5 million, which includes approximately \$3.1 million for its clinical programs for INNO-206, approximately \$4.9 million for its clinical programs for bafetinib, approximately \$0.3 million for its clinical program for tamibarotene, approximately \$0.2 million for its activities for arimoclomol, approximately \$2.0 million for general operation of its clinical programs, and approximately \$7.0 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and actual expenditures may be significantly different from these projections. The Company will be required to obtain additional funding in order to execute its long-term business plan. The fair value of common stock investment in RXi is subject to market fluctuations that could impact the amount of cash the Company generates from any future sales of RXi shares. The Company cannot assure that additional funding will be available on favorable terms, or at all. If the Company fails to obtain additional funding when needed, it may not be able to execute its business plans and its business may suffer, which would have a material adverse effect on its financial position condition.

If the Company obtains marketing approval as currently planned and successfully commercializes its product candidates, the Company anticipates it will take a minimum of three years, and possibly longer, for it to generate significant recurring revenue. The Company will be dependent on future financing and possible asset sales until such time, if ever, as it can generate significant recurring revenue. The Company has no commitments from third parties to provide any additional financing, and it may not be able to obtain future financing on favorable terms, or at all. If the Company fails to obtain sufficient funding when needed, it may be forced to delay, scale back or eliminate all or a

portion of its development programs or clinical trials, license to other companies its product candidates or technologies that it would prefer to develop and commercialize itself, or seek to sell some or all of its RXi shares or other assets or merge with or be acquired by another company. For example, the Company intends to assess periodically the costs and potential commercial value of its molecular chaperone programs, and depending on these assessments, the Company may determine to spin out, modify, out-source, partner or suspend those activities.

11. Equity Transactions

During the six-month period ended June 30, 2010, 223,633 options to purchase the Company's common stock were exercised, and the Company received \$147,243 upon their exercise. No warrant holders exercised their rights to acquire common shares.

12. ALSCRT Amendment

In August 2006, the Company received approximately \$24.3 million in proceeds from the privately-funded ALS Charitable Remainder Trust (“ALSCRT”) in exchange for the commitment to continue research and development of arimoclomol and other potential treatments for ALS and a one percent royalty in the worldwide sales of arimoclomol. Under the arrangement, we retain the rights to any products or intellectual property funded by the arrangement and the proceeds of the transaction are non-refundable. The ALSCRT has no obligation to provide any further funding to the Company. The Company concluded that due to the research and development components of the transaction that it was properly accounted for under ASC 730-20 (previously Statement of Financial Accounting Standards No. 68, Research and Development Arrangements). Accordingly, the Company recorded the value received under the arrangement as deferred service revenue and recognized service revenue using the proportional performance method of revenue recognition, meaning that service revenue was recognized on a dollar-for-dollar basis for each dollar of expense incurred for the research and development of arimoclomol and other potential ALS treatments.

Pursuant to an amendment signed between the Company and the beneficiary of the ALSCRT on August 6, 2009, the Company was released from all restrictions on the use of any proceeds previously paid to the Company in connection with the arrangement. As a result, the Company recognized \$6.7 million as service revenue in the third quarter of 2009, which represented the remaining deferred revenue and previously un-recognized portion of the value received.

13. Subsequent events

Management has evaluated subsequent events and the impact on the reported results and disclosures.

Item 2. — Management’s Discussion and Analysis of Financial Condition And Results of Operations

Forward Looking Statements

From time to time, we make oral and written statements that may constitute “forward-looking statements” (rather than historical facts) as defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations and releases, including Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We desire to take advantage of the “safe harbor” provisions in the Private Securities Litigation Reform Act of 1995 for forward-looking statements made from time to time, including, but not limited to, the forward-looking statements made in this Quarterly Report, as well as those made in our other filings with the SEC.

All statements in this Quarterly Report, including statements in this section, other than statements of historical fact are forward-looking statements for purposes of these provisions, including statements of our current views with respect to the recent developments regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential” or “the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements.

All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, those factors discussed in this section and under the caption “Risk Factors,” in our Annual

Report on Form 10-K for the year ended December 31, 2009, all of which should be reviewed carefully. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Overview

CytRx Corporation (“CytRx,” the “Company,” “we,” “us” or “our”) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology. Our drug development pipeline includes clinical development of three product candidates for cancer indications, including a recently-initiated Phase 2 proof-of-concept clinical trial with bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia, or B-CLL, two planned Phase 2 proof-of-concept clinical trial with bafetinib in patients with glioblastoma multiforme and advanced prostate cancer, three planned Phase 2 clinical trials for INNO-206 as a treatment for pancreatic cancer, gastric (stomach) cancer and soft tissue sarcomas, and a registration study of tamibarotene for the treatment of acute promyelocytic leukemia, or APL. In addition to our core oncology programs, we are developing two drug candidates based on our molecular chaperone regulation technology, which are designed to repair or degrade mis-folded proteins associated with disease. Apart from our drug development programs, we currently maintain a 17% equity interest in our former subsidiary, RXi Pharmaceuticals Corporation (NASDAQ: RXII). Our current business strategy is to possibly spin-out our molecular chaperone regulation technology or seek one or more strategic partnerships to pursue the development of the technology.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, impairment of long-lived assets, including finite lived intangible assets, research and development expenses and clinical trial expenses and stock-based compensation expense.

We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies are summarized in Note 2 to our financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2009. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements:

Revenue Recognition

Revenue consists of license fees from strategic alliances with pharmaceutical companies as well as service and grant revenues. Service revenue consists of contract research and laboratory consulting. Grant revenues consist of government and private grants.

Monies received for license fees are deferred and recognized ratably over the performance period in accordance with Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition. Milestone payments will be recognized upon achievement of the milestone as long as the milestone is deemed substantive and we have no other performance obligations related to the milestone and collectability is reasonably assured, which is generally upon receipt, or recognized upon termination of the agreement and all related obligations. Deferred revenue represents amounts received prior to revenue recognition.

Revenues from contract research, government grants, and consulting fees are recognized over the respective contract periods as the services are performed, provided there is persuasive evidence or an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Once all conditions of the grant are met and no contingencies remain outstanding, the revenue is recognized as grant fee revenue and an earned but unbilled revenue receivable is recorded.

In August 2006, we received approximately \$24.3 million in proceeds from the privately-funded ALS Charitable Remainder Trust (“ALSCRT”) in exchange for the commitment to continue research and development of arimoclomol and other potential treatments for ALS and a one percent royalty in the worldwide sales of arimoclomol. Under the arrangement, we retained the rights to any products or intellectual property funded by the arrangement and the proceeds of the transaction were non-refundable. The ALSCRT has no obligation to provide any further funding to us. We concluded that due to the research and development components of the transaction that it is properly accounted for under ASC 730-20 (previously Statement of Financial Accounting Standards No. 68, Research and Development Arrangements). Accordingly, we recorded the value received under the arrangement as deferred service revenue and recognized service revenue using the proportional performance method of revenue recognition, meaning that service revenue was recognized on a dollar-for-dollar basis for each dollar of expense incurred for the research and development of arimoclomol and other potential ALS treatments. We believe that this method best approximates the efforts expended related to the services provided. We adjusted our estimates of expense incurred for this research and development on a quarterly basis.

The amount of “deferred revenue, current portion” is the amount of deferred revenue that is expected to be recognized in the next twelve months and is subject to fluctuation based upon management’s estimates. Management’s estimates include an evaluation of what pre-clinical and clinical trials are necessary, the timing of when trials will be performed and the estimated clinical trial expenses. These estimates are subject to changes and could have a significant effect on the amount and timing of when the deferred revenues are recognized.

Pursuant to an amendment signed between us and the beneficiary of the ALS CRT on August 6, 2009, we were released from all restrictions on the use of any proceeds previously received by us in connection with the arrangement. As a result, we recognized \$6.7 million as service revenue in the third quarter of 2009, which represented the remaining deferred revenue and previously un-recognized portion of the value received.

Research and Development Expenses

Research and development expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Technology developed for use in its products is expensed as incurred until technological feasibility has been established.

Clinical Trial Expenses

Clinical trial expenses, which are included in research and development expenses, include obligations resulting from our contracts with various clinical research organizations in connection with conducting clinical trials for our product candidates. We recognize expenses for these activities based on a variety of factors, including actual and estimated labor hours, clinical site initiation activities, patient enrollment rates, estimates of external costs and other activity-based factors. We believe that this method best approximates the efforts expended on a clinical trial with the expenses we record. We adjust our rate of clinical expense recognition if actual results differ from our estimates. If our estimates are incorrect, clinical trial expenses recorded in any particular period could vary.

Stock-Based Compensation

Our stock-based employee compensation plans are described in Note 8 of the Notes to Condensed Financial Statements included in this Quarterly Report. We have adopted the provisions of ASC 718 (previously SFAS No. 123(R), Share-Based Payment (“SFAS 123(R)”)), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and non-employees.

For stock options and stock warrants paid in consideration of services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC 718 (previously SFAS No. 123(R)), ASC 505-50 (previously Emerging Issues Task Force Issue No. 96-18 (“EITF 96-18”)), Accounting for Equity Instruments that are Issued to other than Employees for Acquiring, or in Conjunction with Selling Goods or Services and ASC 505 (previously EITF 00-18, Accounting Recognition for Certain Transactions involving Equity Instruments Granted to Other Than Employees), as amended.

Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested.

The fair value of each CytRx common stock option grant is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option-pricing model, based on an expected forfeiture rate that is adjusted for actual experience. If our Black-Scholes option-pricing model assumptions or our actual or estimated forfeiture rate are different in the future, that could materially affect compensation expense recorded in future periods.

Impairment of Long-Lived Assets

We review long-lived assets, including finite lived intangible assets, for impairment on an annual basis, as of December 31, or on an interim basis if an event occurs that might reduce the fair value of such assets below their carrying values. An impairment loss would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted future cash flows or other appropriate fair value methods. If our estimates used in the determination of either discounted future cash flows or other appropriate fair value methods are not accurate as compared to actual future results we may be required to record an impairment charge. The remaining fixed assets from our San Diego laboratory have been re-allocated from Equipment and Furnishings to Assets Held for Sale and written down to their estimated net realizable value at June 30, 2010.

Net Income (Loss) Per Share

Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding. Diluted net income (loss) per common share computed using the weighted-average number of common share and common share equivalents outstanding. Potentially dilutive stock options and warrants of 13.3 million shares and 11.3 million shares, respectively, for the three and six-month periods ended June 30, 2010 and 15.9 million shares and 15.8 million shares, respectively, for the three and six-month periods ended June 30, 2009, were excluded from the computation of diluted loss per share, where the effect would be anti-dilutive.

Warrant Liabilities

Liabilities measured at market value on a recurring basis include warrant liabilities resulting from our recent equity financing. In accordance with ASC 815-40 (formerly EITF (Emerging Issues Task Force) 00-19, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company's Own Stock, the warrant liabilities are being marked to market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with our application of ASC 718 (formerly SFAS 123R). The gain or loss resulting from the marked to market calculation is shown on the Statements of Operations as Gain on warrant derivative liability.

Liquidity and Capital Resources

We have relied primarily upon proceeds from sales of our equity securities and the exercise of options and warrants, and to a much lesser extent upon payments from our strategic partners and licensees, to generate funds needed to finance our business and operations.

At June 30, 2010, we had cash and cash equivalents of approximately \$12.5 million, marketable securities of approximately \$21.0 million, held approximately 3.1 million restricted shares of common stock of RXi with a market value of approximately \$8.0 million based upon the closing price of the RXi common stock on that date. On March 26, 2010, we raised approximately \$3.8 million from the sale of 675,000 RXi shares and on June 30, 2010, we sold 2.0 million shares of the RXi common stock for \$5.0 million, net of costs. Management believes that our current cash on hand, together with our marketable securities and proceeds from possible future sales of RXi common stock, will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2010 and the first six months of 2011 of approximately \$17.5 million, which includes approximately \$3.1 million for our clinical programs for INNO-206, approximately \$4.9 million for our clinical programs for bafetinib, approximately \$0.3 million for our clinical program for tamibarotene, approximately \$0.2 million for our activities for arimoclomol, approximately \$2.0 million for general operation of our clinical programs, and approximately \$7.0 million for other general and administrative expenses. These projected

expenditures are also based upon numerous other assumptions and subject to many uncertainties, and actual expenditures may be significantly different from these projections.

If we obtain marketing approval and successfully commercialize one or more of our product candidates, we anticipate it will take a minimum of three years and possibly longer, for us to generate significant recurring revenue. We will be dependent on future financing and possible asset sales until such time, if ever, as we can generate significant recurring revenue. We have no commitments from third parties to provide us with any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs or clinical trials, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourselves, or seek to sell some or all of our RXi shares or other assets or merge with or be acquired by another company. For example, we intend to assess periodically the costs and potential commercial value of our new-drug discovery activities. Depending on these assessments, we may determine to modify, out-source, partner or suspend these activities.

We realized a net income in the quarter ended June 30, 2010 of \$1.3 million as compared to a \$2.2 million net loss in the quarter ended June 30, 2009, or a difference of \$3.5 million. We recognized no service revenues in the quarter ended June 30, 2010 as compared to \$1.0 million in the comparative quarter because all of the related ALSCRT revenue was completely recognized in 2009 as a result of the amendment of the ALSCRT arrangement discussed previously. Our research and development expenditures were approximately \$1.7 million higher in the current quarter as compared to the quarter ended June 30, 2009, due to increased spending related to the ramp up of our oncology clinical trials. In the quarter ended June 30, 2010, we recognized a gain of approximately \$5.0 million resulting from the sale of 2 million RXi shares. We also recognized an unrealized gain recorded in other comprehensive income on our remaining 3.1 million RXi shares. We had no similar items in the 2009 comparative period.

In the six-month period ended June 30, 2010, we received \$10.4 million of cash from investing activities, compared to a usage of \$11.1 million in the comparable 2009 period. In the current six-month period, we received proceeds from the sale of 2.675 million RXi shares for a total of \$8.9 million. We purchased net marketable securities of \$1.7 million and \$11.0 million, respectively, in the six-month periods ended June 30, 2010 and 2009. We utilized \$0.3 million for capital expenditures in the three-month period ended June 30, 2010 as compared to \$0.1 million in the comparative 2009 period. We do not expect any significant capital spending during the next 12 months.

In the six-month period ended June 30, 2010, we received \$147,000 from the exercise of stock options as compared to none in the comparative period. We continue to evaluate potential future sources of capital, as we do not currently have commitments from any third parties to provide us with additional capital. The results of our technology licensing efforts and the actual proceeds of any fund-raising activities will determine our ongoing ability to operate as a going concern. Our ability to obtain future financings through joint ventures, product licensing arrangements, royalty sales, equity financings, sales of RXi shares, grants or otherwise is subject to market conditions and our ability to identify parties that are willing and able to enter into such arrangements on terms that are satisfactory to us. Depending upon the outcome of our fundraising efforts, the accompanying financial information may not necessarily be indicative of future operating results or future financial condition.

As a development company that is primarily engaged in research and development activities, we expect to incur significant losses and negative cash flow from operating activities for the foreseeable future. There can be no assurance that we will be able to generate revenues from our product candidates and become profitable.

We expect to incur significant losses for the foreseeable future, and there can be no assurance that we will become profitable. Even if we become profitable, we may not be able to sustain that profitability.

Results of Operations

We recorded a net income of approximately \$1.3 million and \$0.7 million for the three-month and six-month periods ended June 30, 2010, respectively, as compared to a net loss of \$2.2 million and \$6.2 million, respectively, for the same periods in 2009. Our net income during the three-month and six-month periods of 2010 resulted solely from gains on the sale of RXi of \$5.0 million and \$8.9 million, respectively.

We recognized no service revenue for the three-month and six-month periods ended June 30, 2010, as compared to \$0.9 million and \$2.4 million, respectively, for the same periods in 2009. The 2009 revenues relate to our \$24.3 million sale to the ALSCRT of a one percent royalty interest in worldwide sales of arimoclomol in August 2006. Pursuant to an amendment signed between us and the beneficiary of the ALSCRT on August 6, 2009, we were released from all restrictions on the use of any proceeds previously paid to us in connection with the arrangement. As a result, we recognized \$6.7 million as service revenue in the third quarter of 2009, which represented the remaining deferred revenue and previously un-recognized portion of the value received. All future licensing fees under our current licensing agreements are dependent upon successful development milestones being achieved by the licensor.

During 2010, we do not anticipate receiving any significant licensing fees.

Research and Development

	Three-Month Period Ended June 30,		Six-Month Period Ended June 30,	
	2010	2009	2010	2009
	(In thousands)		(In thousands)	
Research and development expenses	\$3,002	\$1,020	\$4,975	\$3,695
Non-cash research and development expenses	25	10	53	19
Employee stock option expense	45	172	88	368
Depreciation and amortization	1	162	3	331
	\$3,073	\$1,364	\$5,119	\$4,413

Research expenses are expenses incurred by us in the discovery of new information that will assist us in the creation and the development of new drugs or treatments. Development expenses are expenses incurred by us in our efforts to commercialize the findings generated through our research efforts. Our research and development expenses, excluding stock option expense, non-cash expenses and depreciation expense, were \$3.0 million and \$5.0 million for the three-month and six-month periods ended June 30, 2010, respectively, and \$1.0 million and \$3.7 million, respectively, for the same periods in 2009.

Research and development expenses incurred during the three-month and six-month periods ended June 30, 2010 relate to our various development programs. In the three-month period ended June 30, 2010, the development costs of our program for INNO-206 were \$0.9 million, the costs of our program for bafetinib were \$1.2 million, and the costs of our program for tamibarotene were \$0.1 million. The remainder primarily related to research and development support costs.

As compensation to our consultants, and in connection with the acquisition of technology, we sometimes issue shares of common stock, stock options and warrants to purchase shares of common stock. For financial statement purposes, we value these shares of common stock, stock options, and warrants at the fair value of the common stock, stock options or warrants granted, or the services received, whichever is more reliably measurable. The value of the non-employee option grants are marked to market using the Black-Scholes option-pricing model and most of the compensation expense recognized or recovered during the period is adjusted accordingly. We recorded \$45,000 and \$88,000 of employee stock option expense both during the three-month and six-month periods ended June 30, 2010, respectively, and \$0.2 million and \$0.4 million, respectively, for the same periods in 2009.

General and Administrative Expenses

	Three-Month Period Ended June 30,		Six-Month Period Ended June 30,	
	2010	2009	2010	2009
	(In thousands)		(In thousands)	
General and administrative expenses	\$1,689	\$1,503	\$3,687	\$3,614
Non-cash general and administrative expenses	0	106	479	180
Employee stock option expense	338	297	483	572
Depreciation and amortization	33	22	56	45
	\$2,060	\$1,928	\$4,705	\$4,411

General and administrative expenses include all administrative salaries and general corporate expenses, including legal expenses associated with the prosecution of our intellectual property. Our general and administrative expenses, excluding stock option expense, non-cash expenses and depreciation expense, were \$1.7 million and \$3.7 million for

the three-month and six-month periods ended June 30, 2010, respectively, and \$1.5 million and \$3.6 million, respectively, for the same periods in 2009.

Employee stock option expense relates to options granted to recruit and retain directors, officers and other employees. We recorded approximately \$0.3 million and \$0.5 million of employee stock option expense in the three-month and six-month periods ended June 30, 2010, as compared to \$0.3 million and \$0.6 million, respectively, for the same periods in 2009. We recorded \$0 and \$0.5 million of non-employee stock option expense in the three-month and six-month periods ended June 30, 2010, as compared to \$0.1 million and \$0.2 million, respectively in the prior comparative periods.

Depreciation and Amortization

Depreciation expense reflects the depreciation of our equipment and furnishings. The remaining fixed assets from our San Diego, California laboratory have been re-allocated from Equipment and Furnishings to Assets Held for Sale and written down to their estimated net realizable value at June 30, 2010.

Interest Income

Interest income was \$80,000 and \$0.2 million for each of the three-month and six-month periods ended June 30, 2010, compared to \$72,000 and \$0.1 million for the same periods in 2009.

Item 3. — Quantitative and Qualitative Disclosures About Market Risk

Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because a significant portion of our investments are in short-term debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any derivative financial instruments or foreign currency instruments. If interest rates had varied by 10% in the three-month ended June 30, 2010, it would not have had a material effect on our results of operations or cash flows for that period.

Item 4. — Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rule 13a-15(e)) as of the end of the quarterly period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.

Changes in Controls over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended June 30, 2010 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We continually seek to assure that all of our controls and procedures are adequate and effective. Any failure to implement and maintain improvements in the controls over our financial reporting could cause us to fail to meet our reporting obligations under the SEC's rules and regulations. Any failure to improve our internal controls to address the weaknesses we have identified could also cause investors to lose confidence in our reported financial information, which could have a negative impact on the trading price of our common stock.

PART II — OTHER INFORMATION

Item 1A – Risk Factors

We are subject to a number of risks and uncertainties, including the risks and uncertainties discussed below, as well as those described in our Annual Report on Form 10-K for the year ended December 31, 2009 or reflected in any subsequent filings we make with the SEC. If any of these risks or uncertainties actually occur, our business, results of operations, financial condition and prospects could be materially and adversely affected. In that case, the trading price of our common stock could decline. These risks and uncertainties are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently perceive as immaterial, also may adversely affect us.

Our common stock may be delisted from The Nasdaq Capital Market if the stock price does not increase.

We received notice from The Nasdaq Stock Market on July 14, 2010 that we were not in compliance with the minimum \$1.00 closing bid price required by Nasdaq Marketplace Rule 4310(c)(4) and, in accordance with Marketplace Rule 4310(c)(8)(D), could regain compliance if, by January 10, 2011, the closing bid price of our common stock is at or above \$1.00 for 10 consecutive business days and we otherwise meet the Nasdaq's continuing listing requirements. In its notice to us, Nasdaq also informed us that, if we did not regain compliance by the stated deadline, we would be granted up to an additional 180 calendar days to regain full compliance while continuing to trade during such time if we meet the Nasdaq's initial listing requirements other than the minimum bid price rule. If we eventually fail to comply with this condition for continued listing and our common stock is delisted from The Nasdaq Capital Market, our common stock is expected to be quoted on the Pink Sheets LLC or the OTC Bulletin Board markets. However, there is no assurance that our common stock will, in fact, be quoted on one of these other trading systems or that an active trading market for our common stock will thereafter exist, which would materially and adversely impact the market value of our common stock.

Item 5. Other Information

On June 29, 2010, we held our Annual Meeting of Stockholders. The following are the results of voting on the proposals submitted to a vote of our stockholders:

a) Election of directors:

Nominee	For	Withheld
Lou Ignarro, Ph.D.	19.7 million	5.8 million
Joseph Rubinfeld, Ph.D.	23.6 million	1.9 million

b) Ratification of the selection of BDO Seidman, LLP as our independent auditors:

For	81.6 million
Against	1.3 million
Abstain	0.2 million

Item 6. — Exhibits

The exhibits listed in the accompanying Index to Exhibits are filed as part of this Quarterly Report and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CytRx Corporation

Date: August 9, 2010

By: /s/ JOHN Y. CALOZ
John Y. Caloz
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description
31.1	Certification of Chief Executive Officer Pursuant to 17 CFR 240.13a-14(a)
31.2	Certification of Chief Financial Officer Pursuant to 17 CFR 240.13a-14(a)
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002